<DOC>
	<DOCNO>NCT00974805</DOCNO>
	<brief_summary>This study investigate possible mechanisms action inhale treatment ( Seretide ) , currently use worldwide million patient COPD ( Chronic Obstructive Pulmonary Disease ) improve symptoms patient . Previous research fail identify mechanism play dilation airway . The research community long think mechanism immune base anti inflammatory despite intensive research yet identify .</brief_summary>
	<brief_title>An Investigation Mechanism Action Seretide Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>We aim recruit equal number healthy smoker , mild , moderate severe COPD patient ( 12 patient recruit group ) . These patient never prescribe component present Seretide ( Salmeterol Flixotide similar compound ) . The patient spirometry begin study confirm presence COPD . Healthy smoker define ex current smoker match study population normal lung function . Patients history asthma , bronchiectasis , carcinoma bronchus , significant respiratory disease exclude . The patient total four study visit , 2 treatment 2 treatment , 56 day study period . At study visit induce sputum perform blood extract . The cell fom sample analyse cell type activation . Sputum serum store cytokine analysis later date . The Sputum induce use standardised protocol use nebulised saline solution .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>&gt; 35yrs . &gt; 10 Pack Years COPD define FEV1 &lt; 70 % FEV1/FVC ratio &lt; 70 % Asthma Lung cancer Bronchiectasis</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Bronchitis</keyword>
</DOC>